Robust Biopharmaceutical Pipeline Offers New Hope for Patients

        Robust Biopharmaceutical Pipeline Offers New Hope for Patients

PR Newswire

WASHINGTON, Jan. 17, 2013

Report underscores value of innovation for patients with unmet medical needs

WASHINGTON, Jan. 17, 2013 /PRNewswire-USNewswire/ --The biopharmaceutical
pipeline is innovative and robust, with a high proportion of potential
first-in-class medicines and therapies targeting diseases with limited
treatment options, according to a new report released today by the
Pharmaceutical Research and Manufacturers of America (PhRMA).


Watch PhRMA's live webinar about the report today at 12:00 pm EST.

The report, developed by the Analysis Group and supported by PhRMA, reveals
that more than 5,000 new medicines are in the pipeline globally. Of these
medicines in various phases of clinical development, 70 percent are potential
first-in-class medicines, which could provide exciting new approaches to
treating disease for patients.

"Biopharmaceutical companies, working with other partners in the American
research ecosystem, have made incredible progress in helping confront some of
the most challenging and costly diseases facing patients around the world,"
said John J. Castellani, president and CEO, PhRMA. "With more than 5,000
medicines in development for patients suffering from a wide range of diseases,
there is a palpable excitement around the biopharmaceutical pipeline and the
future opportunities for new, cutting-edge medicines to improve patient care
and bring value to the entire U.S. health care system."

Many of the new medicines in the pipeline are also for diseases for which no
new therapies have been approved in the last decade. For example, there are
158 potential medicines for ovarian cancer, 19 for sickle cell disease and 41
for small cell lung cancer.

Additionally, among other data in the report, the authors found that
personalized medicines account for an increasing proportion of the pipeline,
and the number of potential new medicines for rare diseases averaged 140 per
year in the last 10 years compared to 64 in the previous decade.

"Since 2005, the number of new medicines in development has grown by 40
percent," said John Lechleiter, Ph.D., chairman of PhRMA and chairman,
president, and CEO of Eli Lilly and Company. "Our industry has been able to
advance scientific discovery – along with the roster of potential new
medicines – thanks, in part, to a policy environment that enables medical
innovation to flourish. Public policies that value intellectual property, a
strong regulatory system, and free market access for patients are critical to
maintaining a robust innovation ecosystem and continuing to make progress
fighting disease."

"On the eve of the presidential inauguration and in the midst of challenging
fiscal pressures, we should renew our focus on the benefits of medical
innovation for patient care, the economy and U.S. jobs," continued
Castellani. "The President has continually stressed the importance of
innovation as a cornerstone to improving health and the U.S. economy, but to
achieve these goals, we need patient-centric policies and continued
collaboration among the public and private sectors."

The biopharmaceutical research sector currently supports nearly four million
jobs in the U.S. and the overall impact of the sector on the domestic economy
is $917 billion annually. What's more, over the last decade, PhRMA member
companies alone have invested $500 billion in research and development of new
therapies for a wide range of diseases such as diabetes, heart disease and

The full report by the Analysis Group, as well as an accompanying report
developed by PhRMA, are available on our website (

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents
the country's leading innovative biopharmaceutical research and biotechnology
companies, which are devoted to discovering and developing medicines that
enable patients to live longer, healthier, and more productive lives. Since
2000, PhRMA member companies have invested over $500 billion in the search for
new treatments and cures, including an estimated $49.5 billion in 2011 alone.

Find PhRMA Online:

  oWebsite –
  oFacebook –
  oBlog –
  oTwitter – and
  oYouTube –

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on ensuring the flow of medicines during public health
emergencies, visit

SOURCE Pharmaceutical Research and Manufacturers of America

Contact: Jennifer Wall, +1-202-835-3460
Press spacebar to pause and continue. Press esc to stop.